WEZLANA^®
(ustekinumab)
AMGEN
HK Reg. No. HK-68573, HK-68574 (17 Feb, 2025)   
Composition:¹

• Solution for injection in pre-filled syringe 90 mg/1mL

• Solution for injection in pre-filled syringe 45 mg/0.5 mL

Indication:¹

Wezlana can be used to treat adults and pediatric patients 6 years of age and older with:

• Moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

• Active psoriatic arthritis

References

1. Drugs.com. Wezlana. 1 November 2023. Available from:  https://www.drugs.com/wezlana.html. [Accessed 16 May 2025].